Protalix Surges on Elfabrio and PRX-115 | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20065499

Show notes

Protalix BioTherapeutics is on a strong upward trajectory, fueled by blockbuster drug Elfabrio—now approved with a less frequent dosing schedule in Europe—and a strategic alliance with Chiesi. With sales soaring and the Fabry market projected to hit $3.2 billion by 2031, Elfabrio is poised to capture major share. Their pipeline shines too, with PRX-115—a promising gout treatment—expected to deliver pivotal data by late 2027. Financials are equally impressive: Q2 revenue jumped to $19.9M (up from $15.7M), H1 total hit $53.6M, and R&D costs dropped thanks to new tax incentives. Net income surged to $3.8M, and with over $40M in cash and zero debt, they’re well-positioned to keep advancing their rare kidney disease focus. The outlook? Confident—with encouraging market trends backing their next big bet. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a224b92833a1fd18

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.